Little more than a year after starting a business based on spontaneous tumor models in mice, GenPath Pharmaceuticals Inc. raised $42.7 million in a Series B financing. (BioWorld Today)
Little more than a year after starting a business based on spontaneous tumor models in mice, GenPath Pharmaceuticals Inc. raised $42.7 million in a Series B financing. (BioWorld Today)
When AstraZeneca plc's Iressa failed to improve survival in non-small-cell lung cancer patients as a treatment added to first-line standards of care, executives at Genentech Inc. and partners OSI Pharmaceuticals Inc. and Roche Holdings Inc. got some less-than-inspiring insight into the possible future of Tarceva, a candidate the three have been studying in a similar population. (BioWorld Today)
When AstraZeneca plc's Iressa failed to improve survival in non-small-cell lung cancer patients as a treatment added to first-line standards of care, executives at Genentech Inc. and partners OSI Pharmaceuticals Inc. and Roche Holdings Inc. got some less-than-inspiring insight into the possible future of Tarceva, a candidate the three have been studying in a similar population. (BioWorld Today)
Following Monday's announcement that Genentech Inc.'s Avastin biologics license application now is on file with the FDA, it's rumored that the anti-angiogenesis cancer drug proposed as a first-line therapy for metastatic colorectal cancer could enter the U.S. market within about six months. (BioWorld Today)
Following Monday's announcement that Genentech Inc.'s Avastin biologics license application now is on file with the FDA, it's rumored that the anti-angiogenesis cancer drug proposed as a first-line therapy for metastatic colorectal cancer could enter the U.S. market within about six months. (BioWorld Today)
Human Genome Sciences Inc. said it would terminate development of repifermin in chronic venous ulcers following a disappointing Phase II trial. (BioWorld Today)
Human Genome Sciences Inc. said it would terminate development of repifermin in chronic venous ulcers following a disappointing Phase II trial. (BioWorld Today)
